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SumlTlal~ 
This report examines the effect of an anti-VLA-4 monoclonal antibody (mAb) HP1/2 on antigen- 
induced bronchial hyperreactivity to methacholine, and on eosinophil and T lymphocyte infiltration 
in the airways of guinea pigs sensitized and challenged by aerosolized ovalbumin and used 24 h 
thereafter. The intravenous administration of 2.5 mg/kg of HP1/2, but not of its isotype-matched 
mAb  1E6,  1  h  before  and  4  h  after  antigen inhalation,  markedly inhibited the  increased 
bronchopulmonary responses  to intravenous methacholine, as well as airway  eosinophilia in 
bronchoalveolar lavage (BAL) fluid and in bronchial tissue. HP1/2 also suppressed the antigen- 
induced infiltration of the bronchial wall by CD4 + and CD8 + T  lymphocytes, identified by 
immunohistochemical  technique using specific mAbs that recognize antigenic epitopes of guinea 
pig T cells. Treatment with HP1/2 also resulted in a significant increase in the number of blood 
eosinophils, suggesting that inhibition by anti-VLA-4 mAb of eosinophil recruitment to the 
alveolar compartment may partially account for their accumulation in the circulation. These 
findings indicate that eosinophil and lymphocyte adhesion and subsequent infiltration into the 
guinea pig airways that follow antigen challenge are mediated by V'LA-4. Furthermore, concomitant 
inhibition of antigen-induced  bronchial hyperreactivity and of cellular infiltration by anti-VLA-4 
mAb suggests a relationship between airway inflammation and modifications in the broncho- 
pulmonary function. 
rway infiltration by inflammatory cells, particularly eo- 
sinophils and T lymphocytes, and an exaggerated sensi- 
tivity of the airways to different stimuli, namely bronchial 
hyperreactivity, are characteristic  features of asthma (1, 2). 
The participation of eosinophils in the development of bron- 
chial hyperreactivity is supported by their presence in high 
numbers in bronchial biopsies and bronchoalveolar lavage 
(BAL)  1 fluid from asthmatics (1). Furthermore, the obser- 
vation that most of the infiltrating eosinophils appear degranu- 
lated, as a result of in situ activation (3), suggests an impor- 
tant role for the eosinophil-derived cationic proteins, including 
major basic protein (MBP) and eosinophil peroxidase (EPO), 
in bronchial asthma. Indeed, these proteins appear to be respon- 
sible for the shedding and lysis of the respiratory epithelium 
(4-6), which contributes to increase the airway reactivity to 
bronchoconstrictor stimuli. 
1 Abbreviations used in this paper: APAAP,  alkaline  phosphatase  antialkaline 
phosphate; BAL, bronchoalveolar  lavage; EPO, eosinophil  peroxidase; 
ICAM-1, intercellular  adhesion molecule  1; MBP, major basic protein; 
VCAM-1, vascular  cell adhesion  molecule  1; VLA-4, very late activation 
antigen 4. 
Activated T lymphocytes are also commonly found in the 
bronchial submucosa of asthmatic patients (7-9). It was sug- 
gested  that  switching of CD4 +  T  lymphocytes for  the 
preferential production of Th2-derived cytokines (10-12), such 
as IL-5, a cytokine able to promote the growth, differentia- 
tion, and survival  of eosinophils (13-15),  may induce the 
recruitment and activation of these cells at the site of allergic 
reactions.  Nevertheless,  mobilization of leukocytes into the 
inflamed tissues is initiated by their adhesion to endothelial 
cells. This phenomenon is mediated by the binding of LFA-1 
(CDlla-CD18 complex) to intercellular adhesion molecule 
1 (ICAM-1), which is present on various cell populations, 
including lymphocytes (16), mononuclear cells (17), neutro- 
phils (18), and eosinophils (19). However, the further demon- 
stration that lymphocytes and eosinophils, but not neutro- 
phils, express very late activation antigen 4 (VLA-4) and can 
thus bind to vascular cell adhesion molecule 1 (VCAM-1) 
(20), suggests a selective mechanism for their localization in 
inflammatory sites. 
Recently, Weg et al. (21) demonstrated that the in vitro 
preincubation of rain-labeled guinea pig eosinophils with 
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the o~4 subunit of VLA-4 (22), inhibited their accumulation 
induced by the intradermal administration of various inflam- 
matory agents. In the same study, HP1/2 was shown to bind 
to guinea pig eosinophils,  but not  to neutrophils  (21),  al- 
lowing its use in this species as a tool to investigate the role 
of VLA-4 in the inflammatory and immune reactions involving 
eosinophil  mobilization. 
In the present study, we show that ovalbumin inhalation 
by aerosol-sensitized guinea pigs is followed, 24 h  later, by 
increased sensitivity of the airways to bronchoconstrictor re- 
sponses induced by methacholine. Bronchial hyperreactivity 
is accompanied by increased numbers of eosinophils in the 
airways and in BAL fluid as well as by a rise in the EPO levels 
in the supernatant of BAL fluid, as a marker of in situ activa- 
tion. Antigen-challenged guinea pigs also exhibit increased 
numbers of T  lymphocytes in their bronchial wall,  mostly 
consisting  of the  CD4 +  subtype.  Treatment  of sensitized 
guinea pigs with HP1/2 mAb abrogates antigen-induced bron- 
chial hyperreactivity to methacholine and the cellular infiltra- 
tion in the airways,  suggesting  the involvement of VLA-4 
in these processes.  Our results clearly indicate that VLA-4 
inhibitors may have a promising future to counteract allergic 
airway inflammation and the accompanying alterations in the 
bronchopulmonary  function. 
Materials and Methods 
Sensitization  Procedure and Antigen  Challenge,  Male  Hartley 
guinea pigs (400-600 g;  C. Lebeau,  Gambais,  France) were im- 
munized by aerosolized ovalbumin (Miles, NaperviUe, IL), at 1% 
in sterile 0.9% NaC1 (saline) for 30 min. The procedure was repeated 
48 h later and the animals were exposed to antigen challenge 14-17 d 
after the first inhalation. The day of antigen provocation, guinea 
pigs were exposed for 15 rain to five successive solutions of oval- 
bumin of 0.001, 0.01, 0.1, 0.5, and 1%, respectively (modified from 
reference 23). In rare cases, when the concentration of ovalbumin 
reached 0.1%, animals exhibited labored breathing and coughing. 
Control animals  were sensitized as above and exposed to aero- 
solized sterile saline for 30 rain. The aerosol was delivered into a 
36 L plexiglass chamber using an ultrasonic nebulizer (Ultra-Neb 
99; De Vilbiss Medical, Arcueil, France), which produced particles 
of a mass diameter averaging between 0.5 and 3/~m.  The liquid 
output of the nebulizer was 0.6 ml/min. The animals  were used 
for the in vivo experiments 24 h  after challenge with saline or 
ovalbumin. 
mAbs.  HP1/2 is a mouse IgG1 mAb directed against the o~4 
chain (CD49d) of VLA-4 (22). The cell line was grown as ascites 
and mAbs were purified by protein A and gel filtration chromatog- 
raphy under endotoxin-free conditions, as described (21). Isotype- 
matched mAb  1E6 was  purified as above. 
Treatments.  HP1/2  was  injected  intravenously to  sensitized 
guinea pigs at the dose of 2.5 mg/kg,  1 h before and 4 h after 
antigen challenge.  This dose and route of administration  were 
selected on the basis of results showing that HP1/2 inhibited eo- 
sinophil accumulation in the guinea pig skin induced by the in- 
tradermal injection of different inflammatory agonists (21). Con- 
trol animals were treated intravenously twice with 2.5 mg/kg of 
the isotype-matched mAb 1E6. Aliquots of HP1/2 and 1E6 were 
stored at - 20~  and diluted in sterile saline immediately before use. 
In Vivo Experiments.  The day of the experiment, guinea pigs 
were anesthetized by an intraperitoneal injection of 1.2 mg/kg ethyl 
urethane (Sigma Chemical Co., St. Louis, MO), tracheae were can- 
nulated, and the animals were prepared for the recording of bron- 
chial resistance  to inflation. The jugular vein was cannulated to 
allow drug injections. Spontaneous breathing was suppressed by 
the intravenous injection of 4 mg/kg of pancuronium bromide (Or- 
ganon Teknika,  Fresnes, France). At least 1 h after surgery, bron- 
chial reactivity was tested by the intravenous administration  of 1-64 
#g methacholine (Sigma Chemical Co.) at 15-min intervals. Changes 
in bronchial resistance to inflation were measured by a pressure trans- 
ducer (Gould Electronics BV, Bihhoven, The Netherlands) placed 
between the trachea and the respiratory pump (Palmer BioScience, 
Sheerness, UK) and continuously recorded on a dynograph (model 
R511;  Beckman Instruments,  Schiller Park,  IL). 
Results are expressed as the effective dose of methacholine, cal- 
culated from the dose-response curve, required to increase the bron- 
chial resistance  to inflation by 30% of the maximal response  ob- 
tained by clamping the tracheal  cannula (ED30). 
Blood Leukocyte and Bronchoalveolar Cell Counts and Differentia- 
tion.  In separate experiments, sensitized  guinea pigs challenged 
either with saline or ovalbumin and treated with HP1/2 or 1E6, 
were anesthetized as above and tracheae and carotid arteries were 
cannulated. Aliquots of arterial blood (200/~1) were collected for 
total  leukocyte counts,  using  a  Coulter  Counter  (model ZM; 
Coultronics, Margency,  France),  and for differential  counts after 
staining with Diff-Quik stain (Merz & Dade AG, Baxter Dade AG, 
Duedingen, Switzerland). Results are expressed as number of each 
cell population/#l blood. Bronchoalveolar cells were collected in 
five successive lavages using 10-ml aliquots of sterile saline at room 
temperature injected and recovered through a polyethylene tracheal 
cannula. The lavage fluid was stored on ice and total cell counts 
were performed as above. An aliquot of the suspension  was then 
diluted to reach a final concentration of 1.5  x  10  s cells/ml and 
cytospin preparations were performed (Hettich Universal, Tuttingen, 
Germany). Differential cell counts were obtained by counting 300 
cells after staining with Diff-Quik stain. The results are expressed 
as the concentration of each cell population/ml BAL. Aliquots of 
1 ml of the remaining lavage fluid were centrifuged at 200 g for 
15 rain at 4~  and the supernatant was collected and stored at 
-20~  until the determination of EPO, as described below. The 
corresponding pellet was resuspended in  1 ml of 0.5%  solution 
of NP-40 (Sigma Chemical Co.) in distilled H20 and then stored 
at  -20~  until the measurement of EPO activity. 
EPO Determination.  The levels of EPO in the pellet and in the 
supernatant of BAL fluid from saline-  or ovalbumin-challenged 
guinea pigs treated with HP1/2 or 1E6, as described above, were 
determined by a previously described method (24). Briefly, 100/~1 
of the  substrate  solution  consisting  of 0.1  mM  o-phenylene- 
diaminedihydrochloride (OPD) in 0.05 M Tris-HC1 containing 0.1% 
Triton X-100, and I mM hydrogen peroxide (all from Sigma Chem- 
ical Co.) were added to 100 #1 of the samples in microtiter plate 
wells. The plates were left at 37~  for 30 rain before stopping the 
reaction by the addition ofS0/~1 of 4 M sulfuric acid (Sigma Chem- 
ical Co.). The optical densities were measured at 490 nm (OD490) 
with an automatic microplate-reader (Dinatech MR 5000; Dinatech 
Laboratories,  Saint-Cloud, France). 
Immunohistochemistry.  After the BAL collection was performed 
as described above, guinea pigs were exsanguinated via the abdominal 
aorta and the contents of the thoracic cavity resected  "en bloc" 
The lungs were inflated via the trachea with 3 ml Histocon (Poly- 
sciences, Inc., Warrington, PA), the lobes dissected and mounted 
over cork disks,  covered by optimum cutting temperature com- 
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isopentane (Prolabo, Paris, France) cooled by liquid nitrogen. The 
frozen blocks were kept at  -80~  before use. Sections alongside 
the main intrapulmonary bronchus were cut in a cryostat kept at 
-21~  and collected on glass slides previously coated with poly-L- 
lysine (Sigma Chemical Co.), fixed in chloroform-acetone (vol/vol; 
Merck, Darmstadt, Germany) for 10 min, wrapped in a plastic film, 
and kept at - 20~  before use. Representative sections of each block 
were also stained with hematoxylin-eosin (Rh6ne-Poulenc, Viliers- 
Saint  Paul,  France)  for conventional histology. 
Consecutive sections of each block were stained  with the fol- 
lowing mAbs, as described (25): H159, rat anti-guinea pig T lym- 
phocytes,  staining  90%  circulating  T  cells  (26);  CT5,  mouse 
anti-guinea pig T lymphocytes, staining also macrophages and some 
B cells (27); H155, rat anti-guinea pig CD4, recognizing helper 
T lymphocytes (28), and CT6, mouse anti-guinea pig CDS, recog- 
nizing suppressor/cytotoxic T cells (27). For the rat antibodies, im- 
munoperoxidase staining was performed, employing the Vectastain 
ABC Elite Kit (Vector Laboratories,  Inc., Burlingame, CA); bio- 
tinylated rabbit anti-rat Ig (BA-4001; Vector Laboratories, Inc.) and 
swine anti-rabbit Ig conjugated to horseradish peroxidase (P217; 
Dakopatts a/s, Copenhagen, Denmark) were used together with 
Vectastain. All stainings were followed by diaminobenzidine  (DAB) 
(Sigma Chemical Co.) development and light hematoxylin coun- 
terstaining. For the murine antibodies (CT5 and CT6), alkaline 
phosphatase antialkaline phosphatase (APAAP) staining procedure 
was performed using rabbit Ig to mouse Ig (Z259; Dakopatts) and 
mouse APAAP (D651;  Dakopatts), followed by incubation with 
the substrates  Fast Red TR (Sigma Chemical Co.) and naphtol AS 
MX phosphate (Sigma Chemical Co.), and light hematoxylin coun- 
terstaining. Cyanide-resistant EPO activity, employing potassium 
cyanide (Merck), DAB, and hydrogen peroxide (Merck), was used 
to stain  the eosinophils (25,  29,  30). 
At least two sections stained with each antibody or EPO tech- 
nique, were coded and read in a "blind" fashion. Positive cells were 
enumerated in the bronchial submucosa (between the basal lamina 
and the smooth muscle), and in the bronchial adventitia (between 
the smooth muscle and the cartilage), by means of an eyepiece 
graticule composed of 100 squares of known area. The area of the 
compartments and the number of positive cells were determined 
on each microscope field, and at least 10 fields were analyzed. The 
results of each stained slide were expressed as the number of posi- 
tive cells per unit  area  (6.25  x  104 #m  2,  the total area of the 
graticule). Results were calculated per mAb for each experimental 
group. 
Statistical Analysis.  Results are expressed  as mean  +  SEM of 
the indicated number of experiments. One-way analysis of vari- 
ance  (ANOVA)  was  used to determine significance  among  the 
groups. If a significant  variance was found, an unpaired Student's 
t test was used to assess comparability between means.  A value of 
/0 ~0.05 was  considered significant. 
Results 
Effect of mAb HP1/2 on Antigen-induced  Bronch~l Hyper- 
reactivity to Methacholine.  Ovalbumin inhalation by sensitized 
untreated- or 1E6 (2.5 mg/kg,  i.v.)-treated guinea pigs was 
followed by an augmented bronchoconstrictor response to 
intravenous methacholine, as shown by a significant decrease 
in ED30 values, as compared with saline-challenged guinea 
pigs (Fig.  1). The dose of 2.5 mg/kg HP1/2,  administered 
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Figure 1.  Effect  of HP1/2 on antigen-induced  bronchial hyperreactivity 
to methacholine in sensitized guinea-pigs. Bronchial responsiveness to 
methacholine was evaluated in saline- and ovalbumin-challenged  guinea 
pigs, either untreated or treated intravenously with 2.5 mg/kg 1E6 or 
HP1/2, 1 h before and 4 h after antigen challenge. The baseline bronchial 
resistance to inflation was 6.90 _+ 0.30, 6.90 _+ 0.37, 7.65 _+ 0.66, and 
7.40 +_ 0.47 cmH20 for saline- and ovalbumin-challenged, untreated or 
1E6- or HP1/2-treated-guinea-pigs, respectively (differences  not statisti- 
cally significant). Results are expressed as the effective  dose of methacho- 
line (in micrograms), calculated from the dose-response curve, required 
to increase the bronchial resistance to inflation by 30% of the maximal 
response obtained by clamping the tracheal cannula (ED30). Values are 
means  _+  SEM of 6-9 experiments. 
, p <0.05, as compared with saline-challenged guinea pigs. 
1 h before and 4 h after antigen challenge, inhibited by 92% 
(n  =  6-9, p  =  0.046) bronchial hyperreactivity to methacho- 
line in immunized  guinea pigs  (Fig.  1). 
Effect of mAb HP1/2 on Antigen-induced  Changes in Blood 
Cell Numbers.  Antigen challenge in sensitized guinea pigs 
induced a slight increase in the total number of leukocytes, 
which was more pronounced in 1E6-injected animals (Table 
1). This resulted from a rise in the number of neutrophils 
and  mononuclear  cells,  particularly  in  antigen-challenged 
untreated  animals  (Table  1).  Treatment  with  HP1/2  was 
followed by a significant increase in the number of circulating 
eosinophils,  without  changes  in  that  of other  cell  types 
(Table 1). 
Effect of mAb HP1/2 on Antigen-induced Changes in Cell Com- 
position and EPO Levels in BAL Fluid.  A significant increase 
in the total cell and eosinophil numbers was observed in the 
BAL fluid from antigen-challenged untreated or 1E6-treated 
guinea pigs,  as compared with controls (Table 2). Neutro- 
phil numbers slightly increased after ovalbumin inhalation, 
and a  statistically  significant difference was achieved when 
saline- and ovalbumin-challenged  1E6-treated animals were 
compared (Table 2). No significant changes in the number 
of lymphocytes were observed, even though a trend toward 
an augmentation was noted in antigen- as opposed to saline- 
challenged animals (Table 2). Treatment of sensitized guinea 
pigs with HP1/2 significantly inhibited total cell and eosino- 
phil numbers in the BAL fluid, without modifying the other 
cell populations  (Table 2). 
Ovalbumin inhalation was also followed by a rise in EPO 
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Ovalbumin and Treated Intravenously with  IE6 or HP1/2,  1 h before and 4 h after Antigen  Challenge 
Treatment  Cell Type/#L blood 
Aerosol  Intravenous  Total cells  Eosinophils  Neutrophils  Mononuclear cells 
Saline  None  5,511.5  +_  545.6 
Ovalbumin  None  8,752.0  _+  1,843.1 
Ovalbumin  1E6  7,926.4  +_  808.3* 
Ovalbumin  HP1/2  8,791.8  _+  871.7" 
111.3  _+  38.9 
197.0  _+  28.6 
72.6  _+  14.2 
421.0  _+  89.3"*s 
2,544.6  _+  425.6 
3,661.3  +  1,279.3 
1,823.0  _+  315.8 
2,015.4  +_  378.8 
3,007.3  +_  89.0 
4,829.3  _+  669.3 
5,954.6  +_  751.4" 
6,091.4  +  706.4* 
Values are means  _+  SEM of five experiments. 
" F <0.05,  as compared with saline-challenged guinea pigs. 
p  <0.05,  as compared  with ovalbumin-chaUenged guinea pigs. 
S  p  <0.05,  as compared  with ovalbumin-challenged  1E6-injected guinea pigs. 
Table  2.  Cellular  Distribution in BAL  Fluid Collected  from  Sensitized Guinea Pigs Exposed, 24 h before, to Aerosolized Saline or 
Ovalbumin and Treated Intravenously with  1E6 or HPI/2,  1 h before and 4 h after Antigen  Challenge 
Treatment  Cell type 
Aerosol  Intravenous  Total cells  Macrophages  Eosinophils  Neutrophils  Lymphocytes 
x  lOS/ml BAL 
Saline  None  5.63  _+  1.01  4.10  _+  0.77  0.98  _+  0.12  0.15  _+  0.08  0.14  +  0.07 
Ovalbumin  None  11.01  +  1.03"  6.88  _+  0.85  2.83  +  0.64*  1.10  _+  0.50  0.28  _+  0.11 
Ovalbumin  1E6  10.96  _+  0.65*  7.00  _+  0.41"  2.78  _+  0.64*  0.63  _+  0.16"  0.22  _+  0.11 
Ovalbumin  HP1/2  7.88  _+  1.16s  5.96  _+  0.60  1.06  _+  0.22  *s  0.70  +_  0.14"  0.16  +  0.09 
Values are means  +  SEM of five experiments. 
* p <0.05,  as compared  with saline-challenged guinea pigs. 
* p  <0.05,  as compared  with ovalbumin-challenged  guinea pigs. 
s p  <0.05,  as compared  with ovalbumin-challenged  1E6-injected guinea pigs. 
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Figure 2.  Effect  of HP1/2 on 
antigen-induced  EPO accumula- 
tion in the BAL fluid from sensi- 
tized guinea pigs.  EPO activity 
was measured in the lysed pellet 
(.4) and in the supernatant (/3) of 
BAL fluid from sensitized saline- 
or ovalbumin-challenged guinea 
pigs, either untreated or treated 
intravenously  with 2.5 mg/kg 1E6 
or HP1/2, 1 h before and 4 h after 
antigen  challenge. Results are ex- 
pressed as the mean _+ SEM of five 
experiments for each group. 
, p  <0.05,  as  compared  with 
saline-challenged guinea pigs. 
~p  <0.05,  as  compared  with 
ovalbumin-challenged  guinea pigs. 
S  p  <0.05,  as  compared  with 
ovalbumin-challenged 1E6-inject- 
ed guinea pigs. 
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These effects were markedly inhibited by the administration 
of HP1/2  to sensitized animals (Fig.  2). 
Effect of mAb  HP1/2  on  Antigen-induced Changes in  the 
Number of Eosinophils and  T  Lymphocytes in  the Bronchial 
Wall.  A marked infiltration of eosinophils was seen in the 
bronchial mucosa of ovalbumin-challenged untreated or 1E6- 
treated animals, particularly next to the epithelium (Fig. 3). 
Most of the positive cells were found in the bronchial sub- 
mucosa than in the adventitia (Fig. 4). The intravenous treat- 
ment with 2.5 mg/kg HP1/2 blocked the increase  in the 
number of eosinophils in both compartments (Figs. 3 and 4). 
Ovalbumin inhalation by sensitized untreated or 1E6-treated 
guinea pigs was also followed by T  cell infiltration in the 
bronchial submucosa and the adventitia, as detected by the 
mAb H159 and CT5 (Figs.  5 and 6).  This increment was 
Figure 3.  Cyanide-resistant  eosinophil  peroxidase activity  in the bronchial  wall of sensitized saline- or antigen-challenged  guinea  pigs. (A) saline- 
challenged  animal, showing  scant positive cells in the bronchial submucosa; (/3) ovalbumin-challenged  guinea  pig, with intense  EPO + cells  infiltrating 
the bronchial  submucosa; (C) ovalbumin-challenged  1E6-treated  animal,  also showing  many  EPO + cells  in the bronchial  wall; (D) ovalbumin-challenged 
HP1/2-treated guinea pig with few positive cells in the bronchial submucosa (original magnifications ￿ 
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Figure 4.  Effect  of HP1/2 on eosinophil infiltration into the bronchial lumen of antigen-challenged guinea pigs. EPO + cells in the bronchial sub- 
mucosa (.4) and in the bronchial adventitia (B) of sensitized guinea pigs, challenged with saline or ovalbumin and treated intravenously with 2.5 mg/kg 
1E6 or HP1/2, 1 h before and 4 h after antigen challenge. Results represent the number of positive cells + SEM/unit area of bronchial wall compartment 
(6.25  x  104/2m2). n  ~  5 experiments  for each group. 
p <0.05, as compared with saline-challenged guinea pigs. 
*  p <0.05, as compared with ovalbumin-challenged guinea pigs. 
S  p <0.05, as compared with ovalbumin-challenged  1E6-injected guinea pigs. 
mostly due to CD4 § T cells, even though a significant in- 
crease in the number of CD8 + T cells was observed in the 
bronchial  submucosa  of ovalbumin-,  as opposed to saline- 
challenged animals (Fig. 6). HP1/2 suppressed total T cell 
recruitment, as well as that of CD4 § and CD8 + T lympho- 
cytes in both bronchial  compartments (Figs. 5 and 6). 
Discussion 
Increasing evidence suggests that the frequently observed 
association between activated T lyrnphocytes and eosinophils 
plays a major role in the development  of airway inflamma- 
tion and in the accompanying bronchial hyperreactivity (7-9, 
31). The concomitant presence of infiltrating eosinophils and 
T lymphocytes in the bronchi of asthmatics may result from 
their common pathway of adherence to endothelial cells. In- 
deed, eosinophils bind to activated endothelial  cells by ad- 
hering to VCAM-1  (20), a ligand also involved in lympho- 
cyte adherence to endothelium (32). Furthermore, adhesion 
of eosinophils and lymphocytes to VCAM-1 is mediated by 
the binding of V-LA-4 present on their surface (20, 33), which 
underlines the selectivity of the mechanisms involved in their 
migration into inflamed tissues. 
Upon reaching the airways, eosinophils can release a va- 
riety of cationic proteins,  such as EPO and MBP, that are 
responsible for injury and shedding of airway epithelium (4-6). 
Disruption of the epithelium leads to the exposure of the 
underlying mucosal structures and sensory nerve endings to 
allergen  and  irritants,  contributing to  the developing  of 
nonspecific bronchial  hyperreactivity. 
In the present study, we demonstrate that antigen inhala- 
tion by aerosol-sensitized guinea pigs is followed by a two- 
fold increase in the bronchial reactivity to methacholine. This 
is accompanied by intense eosinophil infiltration in the brow 
chopulmonary tissue and accumulation  in the BAL fluid. 
Under these conditions,  treatment of the sensitized animals 
with the anti-VLA-4 mAb HP1/2 results in a marked inhi- 
bition of antigen-induced bronchial hyperreactivity and eo- 
sinophil infiltration and accumulation in the bronchial wall. 
This suggests that anti-VLA-4 antibody exerts its effect by 
preventing  binding  of VLA-4  located  on  eosinophils  to 
endothelium-associated VCAM-1, leading to the inhibition 
of the recruitment of eosinophils into the bronchopulmo- 
nary tissue. In support, suppression of antigen-induced airway 
eosinophilia in HP1/2-treated animals was accompanied by 
a rise in the number of eosinophils in the blood. 
Weg et al. (21) showed that VLA-4 is involved in eosino- 
phil recruitment at the site of antigen stimulation in the guinea 
pig skin. Here we highlight other facets of VLA-4-medi- 
ated allergic inflammation, such as antigen-induced bronchial 
hyperreactivity and in situ eosinophil activation. In our model, 
eosinophil degranulation was detected by increased concen- 
trations  of EPO in the BAL fluid from antigen-challenged 
guinea pigs. We have previously validated the use of EPO 
as a marker for eosinophil  activation and showed that the 
levels of EPO and MBP, a cationic protein specifically  stored 
Figure 5.  Identification of T lymphocytes and subsets in the bronchial compartments of sensitized saline- or antigen-challenged guinea-pigs treated 
with 1E6 or HP1/2. (A) marked T lymphocyte infiltration  in the bronchial submucosa of ovalbumin-challenged 1E6-treated guinea pig (CT5, APAAP); 
(B) as in A, ovalbumin-challenged HPl/2-treated guinea pig, showing few positive cells. (C) CD4 + T lymphocytes in the bronchial mucosa of lungs 
from sensitized saline-challenged guinea pigs (H155, immunoperoxidase), showing scant positive cells in the bronchial submucosa; (D) as in C, ovalbumin- 
challenged 1E6-treated guinea pig with intense positive CD4 + T lymphocytes infiltrating the bronchial submucosa; (E) as in C and D, ovalbumin- 
challenged HP1/2-treated guinea pig with few positive cells in the bronchial  submucosa (arrows). Original magnifications  x400. 
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Figure  6.  Effect  of HP1/2 on antigen-induced T ]ymphocytes  recruitment into the bronchial compartments of sensitized gumea pigs. T lymphocytes 
(H159, immunoperoxidase and CT5, APAAP) and their subsets (H155, immunoperoxiclase and CT6, APAAP) were identified in the bronchial sub- 
mucosa (A and B) and in the bronchial adventitia (C and D) of sensitized guinea pigs, challenged with saline or ovalbumin and treated intravenously 
with 2.5 mg/kg 1E6 or HP1/2, 1 h before and 4 h after antigen challenge. Results represent the number of positive cells + SEM/unit area of bronchial 
wall compartment (6.25 x  104/zm2). n =  5 experiments for each group. 
,/7 <0.05, as compared with saline-challenged guinea pigs. 
/7 <0.05, as compared with ovalbumin-challenged guinea pigs. 
S/9 <0.05, as compared with ovalbumin-challenged IE6-injected guinea pigs. 
in the eosinophils,  correlated  significantly  (34).  A  marked 
decrease in the amounts of EPO in the BAL fluid of antigen- 
challenged  guinea pigs was observed in HPl/2-treated animals, 
indicating  that  the eosinophils present  in the airways after 
antigen challenge fail to undergo activation and thus do not 
release  cationic proteins. 
Inhibition  of eosinophil secretion by HP1/2 may reflect 
the block of the interaction between VLA-4 and fibronectin 
(35). Indeed, it was recently reported that adherence of eo- 
sinophils to extracellular matrix proteins, such as fibronectin, 
induced their activation, as expressed by enhanced leukotriene 
(LT)C4  production  (31).  The hypothesis that  activation  of 
airway eosinophils is required for the development of bron- 
chial hyperreactivity is supported by our recent study showing 
that antigen inhalation by systemically sensitized guinea pigs 
is followed by a large infiltration of nonactivated eosinophils 
into the BAL fluid, without  any change in bronchial reac- 
tivity to methacholine (34). However, bronchial hyperreac- 
tivity did occur when these eosinophils were stimulated in 
situ  by  the  intratracheally  administered  LTB4.  This  ma- 
neuver was translated  into  the release  of large amounts  of 
MBP and EPO in the BAL fluid, suggesting that activation 
of and secretion by eosinophils recruited to the lungs upon 
antigen challenge were necessary to induce bronchial hyper- 
reactivity in  the guinea pig. 
Very recently, Abraham et al. (36) showed that HP1/2 in- 
hibits antigen-induced  late phase and bronchial hyperreac- 
tivity in the sheep, without reducing significantly the recruit- 
ment of eosinophils to the BAL fluid.  However, the effect 
of HP1/2 on the activation status of eosinophils in vivo was 
not examined.  Our results showing that HP1/2 suppresses 
in vivo antigen-induced eosinophil degranulation  as well as 
the  accompanying  bronchial  hyperreactivity  confirm  our 
previous proposal that  these events are associated (34)  and 
underline the requirement role of VLA-4 for their induction. 
In our hands, only a slight, but significant increase in the 
number of neutrophils was observed in the BAL fluid 24 h 
after  antigen  challenge,  which  confirm  previous  studies 
showing a short-lived rise in this cell population  after an- 
tigen exposure (23, 37). Interestingly, HP1/2 did not affect 
the number of neutrophils in BAL fluid, since these figures 
were still significantly  different than those of saline-challenged 
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anti-VLA-4 mAb that does not affect neutrophil, as opposed 
to eosinophil,  mobilization. 
The participation  of T lymphocytes in the pathogenesis 
of bronchial asthma and the accompanying bronchial hyper- 
reactivity, has been widely demonstrated (31). Indeed, acti- 
vated  CD4 §  T  lymphocytes are found in  the blood and 
bronchial lumen from asthmatics (7-9, 38) and their numbers 
decreased in parallel with clinical improvement upon therapy 
with corticosteroids  (39). 
Recently, interest has been focused on the characterization 
of CD4 + T lymphocytes based on their repertoire of secreted 
cytokines and its possible role in the pathogenesis of allergic 
disorders. Thus, CD4 + T cells from asthmatics preferentially 
elaborate Th2-derived cytokines, such as IL-4 and IL-5, which 
have been shown to enhance IgE synthesis (40), and to act 
specifically on eosinophil survival, activation,  and secretion 
of proinflammatory mediators  (14). Furthermore, IL-4  is 
highly effective  in inducing VCAM expression on endothelial 
cells (41), which, in turn, facilitates the infiltration  of lym- 
phocytes and eosinophils into the inflamed tissues. In this 
respect, mice transgenic for IL-4 exhibit marked eosinophilic 
tissue  infiltration (42).  It  is  interesting to  speculate that 
inhibition of CD4 § T  lymphocyte accumulation by anti- 
VLA-4 antibody would result in decreased IL-4 secretion, 
which in turn may reduce VCAM-1  expression. 
Large numbers of T  lymphocytes,  mainly of the CD4 + 
subset, have  been identified in the bronchial mucosa of antigen- 
challenged guinea pigs (25, 43), even though no temporal 
relationship  with bronchial hyperreactivity and eosinophil 
infiltration  and activation in the airways were demonstrated 
until now. Here, using immunohistochemical  techniques and 
mAbs specific for guinea pig T  cell epitopes, we extended 
our previous  observation  of the presence in the bronchial 
mucosa of systemically sensitized and boosted guinea pigs 
of increased  numbers  of CD4 +  T  lymphocytes and  eo- 
sinophils (25). In the present study, however, the increased 
numbers of T cells in the bronchial wall, particularly in the 
bronchial submucosa, was concomitant with marked bron- 
chial hyperreactivity to methacholine and with eosinophil de- 
granulation. The increase in T cells was mostly accounted 
for by the CD4 § subset, even though a rise in the number 
of CD8 + T lymphocytes was observed in the bronchial sub- 
mucosa.  The invasion  of the  airways by CD8 +  may be 
related to the observation  that asthmatics developing early 
phase responses after allergen  inhalation exhibit  increased 
numbers of suppressor T cells in the BAL fluid accompanied 
by their decrease in the circulation (44). In the present study, 
treatment of sensitized guinea pigs with HP1/2 suppressed 
antigen-induced T lymphocyte  infiltration in both bronchial 
compartments examined. Inhibition of T cell influx resulted 
from the decrease in the number of the CD4 § and CD8 + 
subclasses, as indicated by the staining with mAb H155 and 
CT6, respectively. Furthermore, recent data have shown that 
activated T lymphocytes express fibronectin at their surface 
(45), another site of interaction for VLA-4.  This suggests 
that sites of intervention for anti-VLA-4  mAb, other than 
VLA-4/VCAM-1 interaction, may be involved in the migra- 
tion and activation of leukocytes, particularly of T lympho- 
cytes,  to  inflammatory sites. Taken  together,  our  results 
showing the concomitant inhibition of eosinophil and T cell 
recruitment into the airways of antigen-challenged  animals, 
confirm the involvement  of VLA-4 in the mobilization of 
these two cell types at the site of allergic inflammation. 
The role of adhesion molecules in experimental asthma was 
first demonstrated by Wegner et al. (46), who showed at- 
tenuation of antigen-induced airway eosinophilia in Ascaris- 
sensitive monkeys  upon  treatment with  an  anti-ICAM-1 
antibody.  In this study, bronchial  hyperreactivity was also 
decreased, suggesting again that airway inflammation and 
alterations in lung function are parallel events. Increased ex- 
pression of adhesive  proteins on endothelial cells during allergic 
reactions has also been reported (47-50).  Finally, Hansel et 
al. (51) demonstrated that sputum eosinophils from asthmatics, 
but not from normal individuals, express ICAM-1 at their 
surface. These results indicate that upregulation of adhesive 
proteins on leukocytes, on one side, and on endothelial cells, 
on the other, is a common feature of allergic inflammation. 
Thus, antagonism of adhesion molecules  and/or of their respec- 
tive ligands may have important implications in cellular net- 
works involved  in the development and perpetuation of inflam- 
matory and allergic disorders. 
In conclusion, our findings demonstrate that, as in human 
asthma, activated eosinophils and increased  numbers of  T lym- 
phocytes in the bronchial mucosa, particularly of the CD4 + 
phenotype, accompany bronchial hyperreactivity  in antigen- 
challenged guinea pigs. These modifications are prevented by 
treating the animals with a specific anti-VLA-4  mAb, sug- 
gesting that interventions designed to selectively prevent eo- 
sinophil  and T lymphocyte influx and activation  in target 
tissues, may inhibit allergic inflammation and its consequences 
on the bronchopulmonary function. 
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